Cytokine production by peripheral blood cells following therapy with a combined vaccine of allergen and QbG10

Cytokine production by peripheral blood cells following therapy with a combined vaccine of allergen and QbG10

Bibliographic Details
Main Authors:	Manolova, V, Flace, A, Maurer, P, Saudan, P, Senti, G, Kuendig, T, Bachmann, M
Format:	Journal article
Published:	2008

Similar Items

A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel allergen-independent immunotherapy in patients suffering from grass pollen allergy
by: Senti, G, et al.
Published: (2007)

A double-blind, placebo-controlled phase Ila study investigating CYT003-QbG10 as a novel immunotherapy in patients suffering from house dust mite allergy
by: Kuendig, T, et al.
Published: (2007)

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma.
by: Beeh, K, et al.
Published: (2013)

Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study.
by: Klimek, L, et al.
Published: (2011)

IgG-mediated down-regulation of IgE bound to mast cells: A potential novel mechanism of allergen-specific desensitization
by: Uermösi, C, et al.
Published: (2014)

IgG-mediated down-regulation of IgE bound to mast cells: a potential novel mechanism of allergen-specific desensitization.
by: Uermösi, C, et al.
Published: (2014)

Nanoparticles target distinct dendritic cell populations according to their size
by: Manolova, V, et al.
Published: (2007)

Mechanisms of allergen-specific desensitization.
by: Uermösi, C, et al.
Published: (2010)

Nanoparticles target distinct dendritic cell populations according to their size.
by: Manolova, V, et al.
Published: (2008)

Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated T cell responses in virus-like particle-based vaccines.
by: Gomes, A, et al.
Published: (2017)

Dust mite allergy - New treatment options
by: Haug, S, et al.
Published: (2007)

CYT006-AngQb, a vaccine against hypertension targeting angiotensin II, reduces early-morning and day-time blood pressure
by: Tissot, A, et al.
Published: (2007)

Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial.
by: Senti, G, et al.
Published: (2009)

Allergen-specific immunotherapy: regulatory T cells or allergen-specific IgG?
by: Kündig, T, et al.
Published: (2010)

Novel allergen-independent immunotherapy: positive data from a phase Ila pilot study with CpG contained in virus-like particles
by: Bull, C, et al.
Published: (2007)

QbD not QED
by: Shireesh Apte
Published: (2016-11-01)

Estatística Q.B.
by: Dinis Pestana
Published: (2013-10-01)

QbD not QED
by: Shireesh Apte

The kinetics of a memory B cell response to virus like particles in mice
by: Zabel, F, et al.
Published: (2012)

Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles.
by: Keller, SA, et al.
Published: (2010)

Marketing innovations : QB House
by: Tan, Adeline Qiaowei, et al.
Published: (2008)

Successful Allergen-Specific Immunotherapy: Induction of Unresponsiveness by ‘Vaccination’
by: Martin F. Bachmann, et al.
Published: (2023-12-01)

Viral Particles Drive Rapid Differentiation of Memory B Cells into Secondary Plasma Cells Producing Increased Levels of Antibodies
by: Zabel, F, et al.
Published: (2014)

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.
by: Tissot, A, et al.
Published: (2008)

A universal Influenza A vaccine based on M2 mediates complete protection from lethal infection in mice
by: Schmitz, N, et al.
Published: (2007)

QbD: The cost of doing business
by: Shireesh Apte
Published: (2016-10-01)

Functional genomics of the peripheral blood response to allergen inhalation challenge
by: Kam Sarah HY, et al.
Published: (2010-11-01)

On the role of allergen-specific IgG subclasses for blocking human basophil activation
by: Simon Zinkhan, et al.
Published: (2022-10-01)

Toward QbD Process Understanding on DNA Vaccine Purification Using Design of Experiment
by: Lalintip Hocharoen, et al.
Published: (2021-05-01)

Quick Blood Volume (Qb) and Ultra Filtration Ureum at Haemodialysis Patient
by: Syamsul Arif S. N, et al.
Published: (2015-08-01)

Impact of IL-10 and IL-12B single nucleotide polymorphisms on circulating cytokine level in development of Hashimoto's thyroiditis
by: Julieta Gerenova, et al.
Published: (2016-07-01)

Mitigating the Risks of Generic Drug Product Development: An Application of Quality by Design (QbD) and Question based Review (QbR) Approaches.
by: Manjurul Kader
Published: (2016-09-01)

Dust mite allergy - new treatment option
by: Haug, S, et al.
Published: (2007)

Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs.
by: Klimek, L, et al.
Published: (2014)

Induction of human T-cell and cytokine responses following vaccination with a novel influenza vaccine
by: Skibinski, D, et al.
Published: (2018)

Anti-IgE Qb-VLP Conjugate Vaccine Self-Adjuvants through Activation of TLR7
by: Bassel Akache, et al.
Published: (2016-01-01)

Hubungan antara Ring Exchange dan Ring QB
by: , SISWANDI, et al.
Published: (2005)

Comparative Analysis of the QbD Approach in the Pharmaceutical Industry
by: S. A. Rozhnova, et al.
Published: (2019-11-01)

Versatile function of NF-ĸB in inflammation and cancer
by: Qiang Ma, et al.
Published: (2024-07-01)

Vaccination against GIP for the treatment of obesity.
by: Fulurija, A, et al.
Published: (2008)